

# Laura A Vanblargan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9861190/publications.pdf>

Version: 2024-02-01

29  
papers

5,330  
citations

430754

18  
h-index

501076

28  
g-index

43  
all docs

43  
docs citations

43  
times ranked

8555  
citing authors

#	ARTICLE	IF	CITATIONS
1	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> , 2022, 602, 664-670.	13.7	917
2	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , 2021, 27, 717-726.	15.2	838
3	Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. <i>Cell Host and Microbe</i> , 2021, 29, 477-488.e4.	5.1	700
4	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 490-495.	15.2	577
5	A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. <i>Cell</i> , 2020, 183, 169-184.e13.	13.5	446
6	Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. <i>Cell</i> , 2021, 184, 2316-2331.e15.	13.5	321
7	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021, 596, 103-108.	13.7	222
8	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	13.7	117
9	Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. <i>Cell Reports</i> , 2021, 36, 109364.	2.9	109
10	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> , 0, , .	13.7	101
11	Human IFIT3 Modulates IFIT1 RNA Binding Specificity and Protein Stability. <i>Immunity</i> , 2018, 48, 487-499.e5.	6.6	94
12	Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. <i>Microbiology and Molecular Biology Reviews</i> , 2016, 80, 989-1010.	2.9	93
13	An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections. <i>Cell Reports</i> , 2018, 25, 3382-3392.e3.	2.9	79
14	A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. <i>Immunity</i> , 2021, 54, 2399-2416.e6.	6.6	79
15	A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis. <i>PLoS Pathogens</i> , 2017, 13, e1006178.	2.1	69
16	Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice. <i>Science Translational Medicine</i> , 2022, 14, eabn1252.	5.8	68
17	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55
18	A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. <i>Immunity</i> , 2021, 54, 2159-2166.e6.	6.6	52

#	ARTICLE	IF	CITATIONS
19	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor- $\alpha$ inhibitors. <i>Med</i> , 2021, 2, 1327-1341.e4.	2.2	31
20	Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variants. <i>Nature Biotechnology</i> , 2022, 40, 1336-1340.	9.4	23
21	Broadly neutralizing monoclonal antibodies protect against multiple tick-borne flaviviruses. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	22
22	An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	14
23	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2021, , eabm3302.	5.8	13
24	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques. <i>Med</i> , 2022, 3, 188-203.e4.	2.2	11
25	mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromes. <i>Cell Reports Medicine</i> , 2022, 3, 100653.	3.3	10
26	Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. <i>IScience</i> , 2022, 25, 103602.	1.9	6
27	mRNA-1273 and Ad26.COVS vaccines protect against the B.1.621 variant of SARS-CoV-2. <i>Med</i> , 2022, 3, 309-324.e6.	2.2	6
28	A Powassan virus domain III nanoparticle immunogen elicits neutralizing and protective antibodies in mice. <i>PLoS Pathogens</i> , 2022, 18, e1010573.	2.1	6
29	Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity. <i>Cell Host and Microbe</i> , 2021, 29, 1634-1648.e5.	5.1	5